Since I am on IGNORE you probably won't get this! However, Mr. Golfer, putting your head in the Fairway Bunker(No Offense, I am a golfer too..just a Metaphor) and not addressing contrary views is your loss. I am long, but cautiously optimistic. trying to address both sides of the equation. I am not a Pumper, Basher or Shorter. Just look at my previous posts and objectionably and unbiasedly(not a word) challenge each one. I am not saying any of the below will come to fruition...It's called Dialogue...Pro's and Con's. Can't we discuss the possibilities Pro's and Con's without Labeling Basher, Pumper, Shorter...Look at the list below and tell me where I am off the map of possibilities:
What do you expect:
1) Missed Time lines
2) Over expectations..Under delivery "Golden Quarter" OUCH!!
3) A third capital raise next week..if not this Week!
4) CROI was a flop..great build up sorrowful follow through!!!
5) Delayed data read out on 30 patients world wide..30 Patients!!...OUCH
6) No Pent up demand for a ME TOO CCR5 SC with Rebound issues!
7) Poor management..Not ONE MD USA BP experienced FDA professional
8) NO CCR4 coverage
9) Absolutely Small "N" for Adjunct
10) 96% coverage with ordinary HAART protocol...96% Efficacy...Who needs 2% more with stats like that..Puke or Die!
11) Pro 140 needs Essay evaluation..inconvenient and expensive..just to see if you are a candidate..SAD!!
12) No interest from BP...NONE!!!
13) Total Silence...Post Hoc, Sub group analysis and dosing issues..even with Adjunct!
14) Mono, GvHD and Adjunct cash burners with NO Results..Capital Raise coming your way!
